Alan Skarbnik, MD: In terms of resistance, we know that ibrutinib resistance is mainly driven by BTK [Bruton tyrosine kinase] mutations. PLC-gamma-2 is downstream for that as well, although not as common. Is this the same with acalabrutinib?
Jennifer R. Brown, MD, PhD: The Ohio State Group reported at ASH last year that they did detect the same type of resistance mutations in patients on acalabrutinib as on ibrutinib. These were detected at a median of about 33 months on therapy, mostly in the relapsed setting. There was about a 1-year lag between when they detected them to when the patients progressed.
They did suggest the possibility that they were detecting these mutations a little bit earlier in patients who had switched from ibrutinib to acalabrutinib. We don’t really have long-term data about whether it holds true in the setting of problems and then switching to acalabrutinib might contribute to resistance. The patient numbers are very small, so it’s hard to tell. But part of the reason I lean toward using acalabrutinib first is because I think that it’s probably better for the patient not to get a serious toxicity in the first place. In my experience, toxicity has been much less with acalabrutinib. This is a better approach than letting them get it and then hope it goes away when you switch to a related drug in the class.
Alan Skarbnik, MD: Yeah, I completely agree with that. That’s why I’ve been favoring acalabrutinib as well.
Jennifer R. Brown, MD, PhD: We do have next-generation noncovalent BTK inhibitors that are targeting this C481 mutation. In particular, 2 of them had very nice data in terms of responses. The ArQule, Inc drug and LOXO-305 are looking quite promising in patients who have these mutations. The noncovalent drugs are able to inhibit the mutation as well as wild-type disease.
Alan Skarbnik, MD: Yeah. And then from the phase 1 data, at least from LOXO-305, it looked like the toxicity profile was very, very encouraging. Do you think that’s because of the reversibility of the BTK inhibition?
Jennifer R. Brown, MD, PhD: That’s an interesting question. I think that maintaining intense pressure on BTK is probably important for efficacy. I’m not sure that the reversibility is helping, except if there are some minor off-target effects where the drug is much less potent. Then, maybe the reversibility is helping. But LOXO-305 is the most specific BTK inhibitor of any of them out there, covalent or non-covalent. It’s really quite specific. So, I think that is probably substantially contributing to what appears to be the very excellent toxicity profile.
Transcript edited for clarity.
Leslie Reviews Relevant Data for Treatment of Relapsed/Refractory CLL
May 8th 2024During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.
Read More
Marks Explores Cardiac Toxicities and Dosing Concerns of BTK Inhibitors in CLL
April 26th 2024During a Case-Based Roundtable® event, Stanley M. Marks, MD, moderated a discussion on the impact of cardiac adverse events on patients who receive a Bruton tyrosine kinase inhibitor for chronic lymphocytic leukemia.
Read More
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More